Last reviewed · How we verify
NCT06820762
Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study
Phase 2 trial testing irinotecan liposome(II) plus Ivonescimab via intravenously (IV) Q3W for 4-6 cycles, followed by Ivonescimab until disease progression or intolerable toxicity in SCLC in 40 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | The Second Affiliated Hospital of Dalian Medical University |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 28 February 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2027 |
| Sites | 2 locations across China |
Drugs / interventions tested
- irinotecan liposome(II) plus Ivonescimab via intravenously (IV) Q3W for 4-6 cycles, followed by Ivonescimab until disease progression or intolerable toxicity
Conditions studied
- SCLC — all drugs for SCLC →
Sponsor
The Second Affiliated Hospital of Dalian Medical University
Who can join
Adults 18 to 75, any sex, with SCLC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the efficacy and safety of irinotecan liposome(II) in combination with Ivonescimab as second line treatment for SCLC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06820762
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for SCLC
Currently open trials in the same condition.
- NCT07110103 — Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC · Phase 2 · recruiting
- NCT07145333 — Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07508852 — 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
- NCT06616532 — PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer · Phase 3 · recruiting
- NCT06534762 — Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study · Phase 2 · recruiting
Other The Second Affiliated Hospital of Dalian Medical University trials
Trials by the same sponsor.
- NCT07349225 — Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Sta · Phase 2 · not yet recruiting
- NCT06299904 — Effect of Modified Air-pulse Stimulation on Tracheotomised Patients With Dysphagia After Stroke · NA · unknown
- NCT05707585 — Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage · unknown
- NCT06386614 — Effect of Frontal Transcranial Direct Current Stimulation on BDNF in Stroke Patients With Cognitive Impairment · NA · recruiting
- NCT04971122 — Comparison of the Effects of Trendelenburg Position and Passive Leg Lift on Hemodynamics in Abdominal Surgery Patients · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06820762 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Second Affiliated Hospital of Dalian Medical University
- Last refreshed: 11 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06820762.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing